Abiopharma

🔍 Third Rock Ventures IV, L.P. (Executive)

Company: Tango Therapeutics, Inc. (TNGX)

Report Date: 2025-09-05

Detailed Transactions and Holdings:

• Sold 642,906 shares of Common Stock at $7.0 per share (Direct)
  Date: 2025-09-05 | Code: S | equity_swap_involved: false | shares_owned_after: 14,813,975.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 86,459 shares of Common Stock at $7.0395 per share (Direct)
  Date: 2025-09-08 | Code: S | equity_swap_involved: false | shares_owned_after: 14,727,516.00 | transaction_form_type: 4 | Footnotes: F2, F1

Footnotes:

• F1: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
• F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).